Selling, General, and Administrative Costs: Opthea Limited vs Wave Life Sciences Ltd.

Biotech Giants' SG&A Expenses: A Decade of Strategic Shifts

__timestampOpthea LimitedWave Life Sciences Ltd.
Wednesday, January 1, 201426520412999000
Thursday, January 1, 2015236158710393000
Friday, January 1, 2016447286915994000
Sunday, January 1, 2017503095726975000
Monday, January 1, 2018498894139509000
Tuesday, January 1, 2019519641248869000
Wednesday, January 1, 2020665277442510000
Friday, January 1, 20211841824746105000
Saturday, January 1, 20222482706650513000
Sunday, January 1, 20234189640851292000
Monday, January 1, 202415488619
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Biotech Companies: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. Opthea Limited and Wave Life Sciences Ltd. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Opthea's SG&A expenses surged by over 1,500% from 2014 to 2023, peaking in 2023. In contrast, Wave Life Sciences Ltd. experienced a steady increase, with expenses growing by approximately 70% over the same period. Notably, Wave Life Sciences consistently outspent Opthea, with 2023 expenses nearly 23% higher. These trends highlight differing strategic approaches: Opthea's recent aggressive expansion versus Wave Life Sciences' steady growth. Missing data for 2024 suggests ongoing developments. Understanding these financial strategies offers insights into each company's market positioning and future potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025